satsuma pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.
Company profile
Ticker
STSA
Exchange
Website
CEO
John Kollins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
813039831
STSA stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
20 Jun 23
EFFECT
Notice of effectiveness
9 Jun 23
EFFECT
Notice of effectiveness
9 Jun 23
EFFECT
Notice of effectiveness
9 Jun 23
25-NSE
Exchange delisting
8 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Jun 23
POS AM
Prospectus update (post-effective amendment)
8 Jun 23
Latest ownership filings
SC 13G/A
BML Investment Partners, L.P.
13 Jun 23
4
Peter Kolchinsky
12 Jun 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
12 Jun 23
4
Thomas P. O'Neil
8 Jun 23
4
Rajeev M. Shah
8 Jun 23
4
KEN TAKANASHI
8 Jun 23
4
Michael T Riebe
8 Jun 23
4
Elisabeth Sandoval
8 Jun 23
4
Thomas P Soloway
8 Jun 23
4
John A Kollins
8 Jun 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.53 mm | 19.53 mm | 19.53 mm | 19.53 mm | 19.53 mm | 19.53 mm |
Cash burn (monthly) | (no burn) | 152.75 k | 3.59 mm | 5.51 mm | 3.80 mm | 4.05 mm |
Cash used (since last report) | n/a | 1.82 mm | 42.87 mm | 65.86 mm | 45.33 mm | 48.36 mm |
Cash remaining | n/a | 17.70 mm | -23.34 mm | -46.33 mm | -25.80 mm | -28.83 mm |
Runway (months of cash) | n/a | 115.9 | -6.5 | -8.4 | -6.8 | -7.1 |
Institutional ownership, Q2 2023
26.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 32 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 6.91 mm |
Total shares | 8.93 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BML Investment Partners | 6.44 mm | $4.38 mm |
Growth Equity Opportunities 17 | 2.49 mm | $2.54 mm |
Shin Nippon Biomedical Laboratories | 1.00 k | $0.00 |
Ra Capital Management | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Jun 23 | Sandoval Elisabeth | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.56 | 14,893 | 67.91 k | 0 |
8 Jun 23 | Sandoval Elisabeth | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.46 | 30,000 | 103.80 k | 0 |
8 Jun 23 | Sandoval Elisabeth | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.6 | 20,000 | 92.00 k | 0 |
8 Jun 23 | Sandoval Elisabeth | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 26.99 | 10,000 | 269.90 k | 0 |
8 Jun 23 | Mutya Harsch | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.46 | 30,000 | 103.80 k | 0 |
8 Jun 23 | Mutya Harsch | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.48 | 40,000 | 179.20 k | 0 |
8 Jun 23 | King Thomas Braxton | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.9 | 12,765 | 11.49 k | 0 |
8 Jun 23 | King Thomas Braxton | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.04 | 12,765 | 13.28 k | 0 |
8 Jun 23 | King Thomas Braxton | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.56 | 14,893 | 67.91 k | 0 |
8 Jun 23 | King Thomas Braxton | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.46 | 30,000 | 103.80 k | 0 |